ArticleFrontiers in pharmacology2024

Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China.

Zuojuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.